NM_004360.5:c.2165-1G>C
Variant summary
Our verdict is Likely pathogenic. Variant got 7 ACMG points: 7P and 0B. PM5_SupportingPS4_SupportingPM2_SupportingPVS1_Strong
This summary comes from the ClinGen Evidence Repository: The c.2165-1G>C variant is a canonical splice variant predicted to result in a truncated or absent protein (PVS1_strong, PM5_Supporting). The variant is absent in the gnomAD cohort (PM2_supporting; http://gnomad.broadinstitute.org). The variant has been reported in one proband meeting clinical criteria for HDGC (PS4_supporting; Ambry). In summary, this variant meets criteria to be classified as likely pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_strong, PS4_supporting, PM2_supporting, PM5_Supporting. LINK:https://erepo.genome.network/evrepo/ui/classification/CA396469209/MONDO:0007648/007
Frequency
Consequence
NM_004360.5 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_pathogenic. Variant got 7 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CDH1 | NM_004360.5 | c.2165-1G>C | splice_acceptor_variant, intron_variant | Intron 13 of 15 | ENST00000261769.10 | NP_004351.1 | ||
CDH1 | NM_001317184.2 | c.1982-1G>C | splice_acceptor_variant, intron_variant | Intron 12 of 14 | NP_001304113.1 | |||
CDH1 | NM_001317185.2 | c.617-1G>C | splice_acceptor_variant, intron_variant | Intron 13 of 15 | NP_001304114.1 | |||
CDH1 | NM_001317186.2 | c.200-1G>C | splice_acceptor_variant, intron_variant | Intron 12 of 14 | NP_001304115.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary diffuse gastric adenocarcinoma Pathogenic:2
This sequence change affects an acceptor splice site in intron 13 of the CDH1 gene. RNA analysis indicates that disruption of this splice site induces altered splicing and may result in an absent or altered protein product. This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with hereditary diffuse gastric cancer (internal data). ClinVar contains an entry for this variant (Variation ID: 532459). Studies have shown that disruption of this splice site results in activation of a cryptic splice site, and produces a non-functional protein and/or introduces a premature termination codon (internal data). For these reasons, this variant has been classified as Pathogenic. -
This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. -
not provided Pathogenic:2
PP5, PM2, PS4_supporting, PVS1_strong -
Canonical splice site variant predicted to result in a null allele in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); Identified in individuals undergoing multi-gene panel testing who reported a personal and/or family history of breast, colorectal, and other cancers (Adib et al., 2022); This variant is associated with the following publications: (PMID: 36246616, 34949788) -
CDH1-related diffuse gastric and lobular breast cancer syndrome Pathogenic:1
The c.2165-1G>C variant is a canonical splice variant predicted to result in a truncated or absent protein (PVS1_strong, PM5_Supporting). The variant is absent in the gnomAD cohort (PM2_supporting; http://gnomad.broadinstitute.org). The variant has been reported in one proband meeting clinical criteria for HDGC (PS4_supporting; Ambry). In summary, this variant meets criteria to be classified as likely pathogenic based on the ACMG/AMP criteria applied as specified by the CDH1 Variant Curation Expert Panel (Variant Interpretation Guidelines Version 3.1): PVS1_strong, PS4_supporting, PM2_supporting, PM5_Supporting. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.2165-1G>C intronic pathogenic mutation results from a G to C substitution one nucleotide upstream from coding exon 14 of the CDH1 gene. This nucleotide position is highly conserved in available vertebrate species. This alteration has been detected in an individual with clinical history consistent with hereditary diffuse gastric cancer (Ambry internal data). In silico splice site analysis predicts that this alteration will weaken the native splice acceptor site and may result in the creation or strengthening of a novel splice acceptor site. RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. -
Familial cancer of breast Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at